Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca appoints former UK minister to board

This article was originally published in Scrip

Executive Summary

Baroness Shriti Vadera, the former parliamentary under-secretary of state for economic competitiveness and enterprise in the UK cabinet office and department for business, innovation & skills in the most recent Labour government, has been appointed to AstraZeneca's board as a non-executive director, with effect from 1 January, 2011. She will also become a member of the board's audit committee. Since leaving government, Baroness Vadera has taken on a number of advisory roles including senior advisory to the Korean presidency of the Group of Twenty (G20), adviser to Temasek Holdings and advisor to the government of Dubai on the restructuring of Dubia World's debt. Baroness Vadera will also become a non-executive director of Australian mining conglomerate BHP Billiton on 1 January, 2011.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC011177

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel